Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4⁺ T Cells

Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and it exhibits resistance to common breast cancer therapies. Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and its ligand, PD-L1, have been approved to treat various cancers. However, t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Reem Saleh, Salman M Toor, Sarah Khalaf, Eyad Elkord
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2019-10-01
coleção:	Vaccines
Assuntos:	breast cancer anti-pd-1 anti-pd-l1 tregs immune checkpoints
Acesso em linha:	https://www.mdpi.com/2076-393X/7/4/149
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!